BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36634299)

  • 1. Cancer Risk Associated With
    Cummings S; Alfonso A; Hughes E; Kucera M; Mabey B; Singh N; Eng C
    JCO Precis Oncol; 2023 Jan; 7():e2200415. PubMed ID: 36634299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
    Ngeow J; Sesock K; Eng C
    Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
    Mester JL; Moore RA; Eng C
    Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
    Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
    PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.
    Ngeow J; He X; Mester JL; Lei J; Romigh T; Orloff MS; Milas M; Eng C
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2320-7. PubMed ID: 23066114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53.
    Ni Y; He X; Chen J; Moline J; Mester J; Orloff MS; Ringel MD; Eng C
    Hum Mol Genet; 2012 Jan; 21(2):300-10. PubMed ID: 21979946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.
    Ngeow J; Mester J; Rybicki LA; Ni Y; Milas M; Eng C
    J Clin Endocrinol Metab; 2011 Dec; 96(12):E2063-71. PubMed ID: 21956414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.
    Ni Y; Zbuk KM; Sadler T; Patocs A; Lobo G; Edelman E; Platzer P; Orloff MS; Waite KA; Eng C
    Am J Hum Genet; 2008 Aug; 83(2):261-8. PubMed ID: 18678321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian Clear Cell Carcinoma in Cowden Syndrome.
    Yauy K; Imbert-Bouteille M; Bubien V; Lindet-Bourgeois C; Rathat G; Perrochia H; MacGrogan G; Longy M; Bessis D; Tinat J; Baert-Desurmont S; Blanluet M; Perre PV; Baudry K; Pujol P; Corsini C
    J Natl Compr Canc Netw; 2019 Jan; 17(1):7-11. PubMed ID: 30659124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study.
    Mahdi H; Mester JL; Nizialek EA; Ngeow J; Michener C; Eng C
    Cancer; 2015 Mar; 121(5):688-96. PubMed ID: 25376524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
    Bubien V; Bonnet F; Brouste V; Hoppe S; Barouk-Simonet E; David A; Edery P; Bottani A; Layet V; Caron O; Gilbert-Dussardier B; Delnatte C; Dugast C; Fricker JP; Bonneau D; Sevenet N; Longy M; Caux F;
    J Med Genet; 2013 Apr; 50(4):255-63. PubMed ID: 23335809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head circumference in the clinical detection of PTEN hamartoma tumor syndrome in a clinic population at high-risk of breast cancer.
    Shiovitz S; Everett J; Huang SC; Orloff MS; Eng C; Gruber SB
    Breast Cancer Res Treat; 2010 Nov; 124(2):459-65. PubMed ID: 20349131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
    Ngeow J; Eng C
    Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KLLN epigenotype-phenotype associations in Cowden syndrome.
    Nizialek EA; Mester JL; Dhiman VK; Smiraglia DJ; Eng C
    Eur J Hum Genet; 2015 Nov; 23(11):1538-43. PubMed ID: 25669429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome.
    Hartsough E; DeSimone MS; Lorenzo ME; Dias-Santagata D; Nose V; Hoang MP
    Am J Clin Pathol; 2024 May; 161(5):490-500. PubMed ID: 38206110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
    Bennett KL; Mester J; Eng C
    JAMA; 2010 Dec; 304(24):2724-31. PubMed ID: 21177507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN hamartoma tumor syndromes in childhood: description of two cases and a proposal for follow-up protocol.
    Piccione M; Fragapane T; Antona V; Giachino D; Cupido F; Corsello G
    Am J Med Genet A; 2013 Nov; 161A(11):2902-8. PubMed ID: 24123798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.
    Ngeow J; Stanuch K; Mester JL; Barnholtz-Sloan JS; Eng C
    J Clin Oncol; 2014 Jun; 32(17):1818-24. PubMed ID: 24778394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifetime cancer risks in individuals with germline PTEN mutations.
    Tan MH; Mester JL; Ngeow J; Rybicki LA; Orloff MS; Eng C
    Clin Cancer Res; 2012 Jan; 18(2):400-7. PubMed ID: 22252256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer.
    Agrawal S; Eng C
    Hum Mol Genet; 2006 Mar; 15(5):777-87. PubMed ID: 16436456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.